In (AD), reduced O-GlcNAcylation promotes tau hyperphosphorylation and aggregation into neurofibrillary tangles, while OGA inhibition can restore tau O-GlcNAcylation, reduce abnormal phosphorylation and aggregation, improve cognitive function, and decrease amyloid-β levels (133, 134). The gene discussed is MAPT; the disease is Alzheimer disease.